Loading...
XSHE002788
Market cap424mUSD
Jan 09, Last price  
8.01CNY
1D
-0.99%
1Q
-5.99%
Jan 2017
-62.83%
IPO
-25.76%
Name

Luyan Pharma Co Ltd

Chart & Performance

D1W1MN
XSHE:002788 chart
P/E
8.56
P/S
0.16
EPS
0.94
Div Yield, %
10.93%
Shrs. gr., 5y
1.99%
Rev. gr., 5y
11.53%
Revenues
19.85b
+1.97%
2,948,581,4964,687,352,4365,519,752,1556,299,801,6936,625,719,8756,982,884,9848,338,232,82311,500,890,95515,008,876,11815,531,278,46117,545,397,26719,462,501,27719,845,534,614
Net income
364m
+5.32%
63,624,64090,513,942108,283,121109,327,452113,479,743115,523,095130,578,913180,324,647255,888,916266,627,871305,870,612345,155,498363,530,313
CFO
1.31b
+463.82%
28,006,22200177,889,035219,30800126,770,170077,222,6450232,186,4451,309,117,195
Dividend
Jul 04, 20240.3 CNY/sh
Earnings
May 07, 2025

Profile

Luyan Pharma Co.,Ltd. engages in the research and development, production, and sale of human health products in China. It also operates pharmaceutical distribution and retail direct stores. The company was formerly known as Luyan (Fujian) Pharma Co. Ltd. and changed its name to Luyan Pharma Co.,Ltd. in June 2016. Luyan Pharma Co.,Ltd. was founded in 1992 and is headquartered in Xiamen, China.
URL
https://www.luyan.com.cn/
IPO date
Feb 18, 2016
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
19,845,535
1.97%
19,462,501
10.93%
Cost of revenue
19,094,176
18,431,593
Unusual Expense (Income)
NOPBT
751,359
1,030,909
NOPBT Margin
3.79%
5.30%
Operating Taxes
104,927
115,036
Tax Rate
13.97%
11.16%
NOPAT
646,431
915,873
Net income
363,530
5.32%
345,155
12.84%
Dividends
(340,103)
(116,555)
Dividend yield
9.74%
3.60%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
3,990,156
4,535,903
Long-term debt
727,286
579,482
Deferred revenue
39,756
41,198
Other long-term liabilities
90,978
118,242
Net debt
4,062,287
4,462,306
Cash flow
Cash from operating activities
1,309,117
232,186
CAPEX
(529,208)
Cash from investing activities
(534,244)
Cash from financing activities
184,461
FCF
1,062,400
237,882
Balance
Cash
606,303
594,190
Long term investments
48,853
58,889
Excess cash
Stockholders' equity
2,348,893
2,140,054
Invested Capital
7,750,788
7,940,433
ROIC
8.24%
12.17%
ROCE
9.69%
12.97%
EV
Common stock shares outstanding
388,517
388,517
Price
8.99
7.92%
8.33
6.66%
Market cap
3,492,765
7.92%
3,236,344
6.66%
EV
7,585,734
7,768,486
EBITDA
871,973
1,143,686
EV/EBITDA
8.70
6.79
Interest
228,019
219,104
Interest/NOPBT
30.35%
21.25%